Karl Broich, DrMed
- Federal Institute for Drugs and Medical Devices (BfArM), Germany
Physician, MD (certifications in Neurology, Psychiatry, Behavioural Psychotherapy). BfArM in Bonn (Germany): 2000 to 2014 several executive functions, since 08/2014 head (President). Work in several EMA committees. Current research: clinical trials methodology CNS, biomarkers in drug development, Alzheimer’s disease and other neurodegenerative disorders.
Kemal Z. Malik
- Member of the Board of Management
- Bayer, Germany
Michael James Doherty
- Head of Product Development
- Foundation Medicine, United States
Head of regulatory affairs at Roche and Genentech from 2002 to 2016. Currently head of strategic innovation at Roche and Executive adviser to Foundation Medicine.
- Senior Advisor, Integrated Development
- Bill and Melinda Gates Foundation, United States
Dr. Ian Hudson has a leading role on the team in areas that include optimizing clinical studies and strengthening regulatory systems in Africa and other low-resource regions, particularly for malaria, polio, and COVID-19 drugs. Ian was a practicing pediatrician before joining SmithKline Beecham in 1989 to work in research and development. In 2001, he joined the UK government’s MHRA, where he served as director of licensing and then CEO. Ian was the UK delegate to the scientific committee of EMA’s Management Board, CHMP, later becoming its vice chair. He was also an honorary senior lecturer in clinical pharmacology at the University of London and served as chair of the International Coalition of Medicines Regulatory Authorities.
Joseph Scheeren, PharmD
- Scheeren Health Care LLC, United States
Dr. Scheeren worked in R&D in the Pharmaceutical Industry for over 35 years in the USA, China and Europe. Former Chair of DIA. Currently , he is a Board Member of VacciTech plc. He recently founded a consultancy company ScheerenHeathCare LLC. Since January 2019, he is Adjunct Professor at Peking University for Regulatory Sciences. He was President and CEO of the C-Path Institute from 19-21. Dr. Scheeren serves on the Forum of the NAS, on Advisory Boards at the CIRS, the Regulatory Affairs Track at Yale University, the CoRE in Singapore, the College of Pharmacy at the UA. He is also a foreign member of the Academie Nationale de Pharmacie in France, and a lecturer at Yale University. Dr. Scheeren studied pharmacy at the University of Leiden.
Tomas Salmonson, DrMed, PhD
- Consilium Salmonson and Hemmings, Sweden
Tomas Salmonson, M.Sc., PhD, brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency in Uppsala, Sweden. He has been a member of the Committee for Medicinal Products for Human Use (CHMP) for more than 12 years. In 2012, Dr Salmonson was elected chair of the CHMP; he was Vice chair of the CHMP from 2007 till 2012. Tomas has been DIA Advisory Council of Europe Member during 1996-2002 and a speaker in over 20 DIA Events.
Susan Forda, PhD
- VP, GLobal Regulatory Affairs International
- Eli Lilly & Company Ltd., United Kingdom
Sue is a PhD pharmacist. After university she joined SmithKline Beecham Pharmaceuticals followed by Eli Lilly and now is VP for International regulatory affairs. She is currently Chair of the EFPIA “Adaptive Models Priority Working Group”.
Sarah Garner, PhD
- Acting Program Manager, Access to Medicines and Health Products
- World Health Organization, Denmark
Professor Sarah Garner is a pharmacist specialising in the interface between Health Technology Assessment (HTA) and regulation. Sarah is the Associate Director for Scientific Policy and Research at NICE and an honorary professor at UCL and Manchester University. She leads Work Packages of the GetReal and ADAPT SMART projects funded by the EU Innovative Medicines Initiative.